

# Christoffer Gebhardt

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1000733/christoffer-gebhardt-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78  
papers

4,777  
citations

25  
h-index

69  
g-index

94  
ext. papers

5,929  
ext. citations

6.4  
avg, IF

5.04  
L-index

#	Paper	IF	Citations
78	Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2022</b> , 36 Suppl 1, 49-52	4.6	1
77	Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 17	9.8	0
76	Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities.. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 102, 102322	14.4	3
75	Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19 Suppl 1, 37-39	1.2	0
74	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
73	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. <i>European Journal of Cancer</i> , <b>2021</b> , 143, 43-45	7.5	1
72	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 1763-1771	4.9	0
71	Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. <i>Cellular Immunology</i> , <b>2021</b> , 360, 104274	4.4	3
70	Adjuvant pembrolizumab-related hyperprogression in stage III melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1341-1345	1.2	
69	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1926-1934	7.5	1
68	Adjuvante Pembrolizumab-assoziierte Hyperprogression eines Melanoms im Stadium III. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1341-1345	1.2	
67	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 68-76	7.5	6
66	Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1001-1015	7.9	8
65	Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3462-3477	7.5	28
64	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. <i>European Journal of Cancer</i> , <b>2019</b> , 111, 148-154	7.5	115
63	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. <i>European Journal of Cancer</i> , <b>2019</b> , 113, 47-54	7.5	174
62	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 765-772	7.4	23

61	Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance - the impact of immunosuppression on frequency of cSCC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33 Suppl 8, 33-37	4.6	13
60	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies <b>2019</b> , 7, 343		24
59	Expression of Neural Crest Markers GLDC and ERFF1 is Correlated with Melanoma Prognosis. <i>Cancers</i> , <b>2019</b> , 11,	6.6	7
58	Liquid biopsy to monitor melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2018</b> , 16, 405-414	1.2	14
57	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 830-842	5.5	34
56	STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon- $\gamma$ <i>Melanoma Research</i> , <b>2018</b> , 28, 204-210	3.3	6
55	Liquid Biopsy zur Berwachung von Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2018</b> , 16, 405-416	1.2	6
54	Extracorporeal Shock Wave Therapy Enhances Receptor for Advanced Glycated End-Product-Dependent Flap Survival and Angiogenesis. <i>Annals of Plastic Surgery</i> , <b>2018</b> , 80, 424-431	1.7	3
53	Multiple epidermotropic melanoma metastases developing during and inhibitor therapy. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 129-131	1.4	
52	CCR5 Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. <i>Cancer Research</i> , <b>2018</b> , 78, 157-167	10.1	82
51	Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma <b>2018</b> ,		5
50	Malignes Melanom beim alten und geriatrischen Patienten <b>2018</b> , 527-534		
49	Letter to the Editor: Role of mutational status of GNAQ and GNA11 in the diagnosis of melanocytic tumors. <i>Journal of Neurosurgery</i> , <b>2017</b> , 126, 1024-1026	3.2	1
48	Endothelial Notch1 Activity Facilitates Metastasis. <i>Cancer Cell</i> , <b>2017</b> , 31, 355-367	24.3	161
47	CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 1015-1023	7.4	56
46	Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. <i>Stem Cell Reports</i> , <b>2017</b> , 8, 1379-1391	8	25
45	Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, e375-e377	4.6	4
44	Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 1907-1917	7.5	6

43	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , <b>2017</b> , 47, 789-802.e9	32.3	142
42	Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair. <i>Nucleic Acids Research</i> , <b>2017</b> , 45, 10595-10613	20.1	37
41	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature</i> , <b>2017</b> , 547, 222-226	50.4	1153
40	Myeloid-derived suppressor cells and tumor escape from immune surveillance. <i>Seminars in Immunopathology</i> , <b>2017</b> , 39, 295-305	12	49
39	D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 914-921	7.5	17
38	A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy. <i>Annals of Oncology</i> , <b>2017</b> , 28, xi14-xi15	10.3	5
37	The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation. <i>Oncotarget</i> , <b>2017</b> , 8, 103682-103692	3.3	17
36	Malignes Melanom beim alten und geriatrischen Patienten <b>2017</b> , 1-8		
35	Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. <i>Scientific Reports</i> , <b>2016</b> , 6, 29914	4.9	70
34	MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2257-62	7.5	11
33	Predictive immune markers in advanced melanoma patients treated with ipilimumab. <i>Oncolmunology</i> , <b>2016</b> , 5, e1158901	7.2	16
32	TGF- $\beta$ induces SOX2 expression in a time-dependent manner in human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 453-8	4.5	21
31	Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 158-64	1.2	19
30	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. <i>Vaccines</i> , <b>2016</b> , 4,	5.3	187
29	Eignung und Probleme von Serum S100B als Biomarker zur Verlaufskontrolle bei Hochrisiko-Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 158-165	1.2	
28	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. <i>Stem Cells</i> , <b>2016</b> , 34, 832-46	5.8	18
27	The GNAQ in the haystack: intramedullary meningeal melanocytoma of intermediate grade at T9-10 in a 58-year-old woman. <i>Journal of Neurosurgery</i> , <b>2016</b> , 125, 53-6	3.2	6
26	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5487-5496	12.9	373

25	T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1369-81	7.4	5
24	Complete remission of treatment-refractory advanced angiosarcoma of the scalp by protracted intralesional interleukin-2 therapy. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1156-8	4	4
23	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5453-9	12.9	237
22	New therapeutic options for advanced non-resectable malignant melanoma. <i>Advances in Medical Sciences</i> , <b>2015</b> , 60, 83-8	2.8	37
21	Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2352-60	7.5	112
20	Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2607-17	7.5	22
19	Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib. <i>Acta Dermato-Venereologica</i> , <b>2015</b> , 95, 96-7	2.2	3
18	The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment—Differences between the patient's and the physician's perspective.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e20099-e20099	2.2	
17	Myeloid-derived suppressor cells in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-7	1.2	33
16	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-1027	1.2	13
15	Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. <i>Medicine (United States)</i> , <b>2014</b> , 93, e161	1.8	7
14	Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient—letter. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2498-9	12.9	4
13	RAGE ligand S100A8/A9 as a novel prognostic biomarker for high-risk melanoma patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9070-9070	2.2	
12	The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS9113-TPS9113	2.2	
11	Identification of the RAGE-dependent gene regulatory network in a mouse model of skin inflammation. <i>BMC Genomics</i> , <b>2010</b> , 11, 537	4.5	17
10	S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. <i>Hepatology</i> , <b>2009</b> , 50, 1251-62	11.2	108
9	Standards und Trends bei der Behandlung des malignen Melanoms. <i>Onkopipeline</i> , <b>2009</b> , 2, 101-113		
8	RAGE signaling sustains inflammation and promotes tumor development. <i>Journal of Experimental Medicine</i> , <b>2008</b> , 205, 275-85	16.6	306

7	S100A8 and S100A9 in inflammation and cancer. <i>Biochemical Pharmacology</i> , <b>2006</b> , 72, 1622-31	6	505
6	A novel aspartic proteinase-like gene expressed in stratified epithelia and squamous cell carcinoma of the skin. <i>American Journal of Pathology</i> , <b>2006</b> , 168, 1354-64	5.8	15
5	c-Fos-dependent induction of the small ras-related GTPase Rab11a in skin carcinogenesis. <i>American Journal of Pathology</i> , <b>2005</b> , 167, 243-53	5.8	39
4	Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. <i>International Journal of Cancer</i> , <b>2003</b> , 104, 699-708	7.5	51
3	Myeloid cell function in MRP-14 (S100A9) null mice. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 2564-76	4.8	172
2	Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. <i>Oncogene</i> , <b>2002</b> , 21, 4266-76	9.2	106
1	Keratinocyte-specific onset of serine protease BSSP expression in experimental carcinogenesis. <i>Journal of Investigative Dermatology</i> , <b>2001</b> , 117, 634-40	4.3	22